Sélectionner la langue
EpCAM
EpCAM Informations sur la molécule
| Nom anglais | Epithelial cell adhesion molecule | Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 12 | Alias de la cible | Epithelial Cell Adhesion Molecule，Tumor-Associated Calcium Signal Transducer 1，Major Gastrointestinal Tumor-Associated Protein GA733-2，Cell Surface Glycoprotein Trop-1，Epithelial Glycoprotein 314，TROP1，KSA，Membrane Component， Chromosome 4， Surface Marker (35kD Glycoprotein)，Antigen Identified By Monoclonal Antibody AUA1，Human Epithelial Glycoprotein-2，Epithelial Cell Surface Antigen，CD326 Antigen，HEGP314，HNPCC8，Ep-CAM，DIAR5，EGP-2，EGP40，KS1/4，MK-1，M1S2，ESA，Ly74，TACST-1，CO-17A，17-1A，EGP34，HEA125，MH99，MOC31，323/A3，Trophoblast Cell Surface Antigen 1，Adenocarcinoma-associated antigen，EGP314，GA733-2，M4S1，TACSTD1，Epithelial glycoprotein，EGP，KS 1/4 antigen，MIC18，CD326，EPCAM |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Epithelial cell adhesion molecule |
| Alias de la cible | Epithelial Cell Adhesion Molecule，Tumor-Associated Calcium Signal Transducer 1，Major Gastrointestinal Tumor-Associated Protein GA733-2，Cell Surface Glycoprotein Trop-1，Epithelial Glycoprotein 314，TROP1，KSA，Membrane Component， Chromosome 4， Surface Marker (35kD Glycoprotein)，Antigen Identified By Monoclonal Antibody AUA1，Human Epithelial Glycoprotein-2，Epithelial Cell Surface Antigen，CD326 Antigen，HEGP314，HNPCC8，Ep-CAM，DIAR5，EGP-2，EGP40，KS1/4，MK-1，M1S2，ESA，Ly74，TACST-1，CO-17A，17-1A，EGP34，HEA125，MH99，MOC31，323/A3，Trophoblast Cell Surface Antigen 1，Adenocarcinoma-associated antigen，EGP314，GA733-2，M4S1，TACSTD1，Epithelial glycoprotein，EGP，KS 1/4 antigen，MIC18，CD326，EPCAM |
| Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 12 |
| Phase de R&D la plus avancée | Approved |
EpCAM Liste de produits
- Attribut
Protein (12)Antibody (1)Cell (1)
- Bibliothèque de produits
En ligne (14)
- Espèces
Human (10)Mouse (1)Rhesus macaque (2)Rabbit (1)
- Étiquette
Fc Tag (2)His Tag (4)His Tag & Avi Tag (2)Fc Tag & Avi Tag (1)Mouse IgG Fc Tag (1)Llama IgG Fc Tag (1)- (2)Tag Free (1)
- Marqueur
Unconjugated (8)Biotin-labeled (3)FITC Labeled (2)- (1)
Ajouter au panier
Quantité totale14
- 1
- 2
EpCAMContexte de la molécule
EpCAM is also known as CO171A, EGP, EGP40,GA7332, KSA, M4S, MIC18, MK1, TROP1, hEGP2, and is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas as 17-1A(mAb) antigen. Its constitutional function is being elucidated. It is intricately linked with the Cadherin-Catenin pathway and hence the fundamental WNT pathway responsible for intracellular signaling and polarity. The epithelial cell adhesion molecule (Ep-CAM) is known to express in most epithelial malignancies and was reported as a tumor marker or a candidate of molecular targeting therapy.
Ep-CAM cross signaling with N-cadherin involves Pi3K, resulting in the abrogation of the cadherin adhesion complexes in epithelial cells was reported. And Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention as a prognostic factor in breast cancer.
EpCAMAlias de la molécule
EPCAM,TACSTD1,TROP1,CD326,DIAR5,EGP2,EGP314,EGP40,ESA,GA733-2,HNPCC8,HNPCC-8,KS1,4,KSA,M4S1,MIC18,MK1
Plateforme de commerce de projets d'anticorps
| Nom du projet | Phase du projet | Type de molécule | Source de molécule | Domain thérapeutique | Indication |
|---|---|---|---|---|---|
| EpCAM CAR-T -01 | IIT | CAR | Humanized Mouse | Solid Tumor | Gastric Cancer |
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Recombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd) | M-701 | Phase 3 Clinical | Wuhan Yzy Biopharma Co Ltd | Ascites; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hydrothorax; Neoplasms; Ovarian Neoplasms; Pleural Effusion, Malignant; Solid tumours; Stomach Neoplasms | Details |
| Oportuzumab monatox | 4D5MOCB-ETA; VB4-845; VB-4847; B-4845; VB-845 | Phase 3 Clinical | Sesen Bio Inc, Viventia Biotech Inc | Carcinoma, Squamous Cell; Head and Neck Neoplasms; Mouth Neoplasms; Neoplasms, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |
| Anti-EPCAM CAR-T cell therapy (Sinobioway) | Phase 2 Clinical | Beijing Sinobioway Bioengineering Group Co Ltd | Liver Neoplasms; Stomach Neoplasms | Details | |
| DuoBody-EpCAMx4-1BB | BNT314/GEN1059; GEN-1059; GEN1059; BNT314 | Phase 2 Clinical | Biontech Se, Genmab A/S | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| IMC-001(Immunofoco) | IMC001; IMC-001 | Phase 2 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| BA-3182 | BA-3182 | Phase 1 Clinical | Bioatla | Adenocarcinoma; Solid tumours | Details |
| KK-2269 | KK-2269; KK2269 | Phase 1 Clinical | Kyowa Kirin Inc | Carcinoma, Non-Small-Cell Lung; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| AM-928 | AM-928 | Phase 1 Clinical | AcadeMab Biomedical Inc | Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours; Thyroid Carcinoma, Anaplastic | Details |
| Varsetatug masetecan | CX-2051; Varseta-M | Phase 1 Clinical | Cytomx Therapeutics Inc, Immunogen Inc | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| 99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3; 99mTc-(CO)3-(HE)3-Ec1; [99mTc]Tc(CO)3-(HE)3-Ec1 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms; Solid tumours | Details |
| A-337 | A-337 | Phase 1 Clinical | Evive Biotech Ltd | Neoplasms; Solid tumours | Details |
| PMC2129G12 | PMC2129G12 | Forevertech Biotechnologies Co Ltd | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Catumaxomab | LP000 | Approved | Neovii Biotech Gmbh, Trion Research | Removab, Korjuny | EU | Ascites | Lindis Biotech GmbH | 2009-04-20 | Ascites; Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
Avis sur les produits
A***O2025-07-30
0Mettre un likeI tested the FITC-EpCAM protein for binding to our anti-EpCAM CAR-T cells which were made by lentiviral transduction of human T cells . The protein stained the CAR-T cells but not the control T cells at both 10 ug/ml and 2 ug/ml. It's a good product.- K***n2023-05-03 1Mettre un likeOverall, we were very pleased with the entire process of buying and using the product—shipping was quick and the product was packaged and stored well. The protein was used in the development of a lateral-flow immunoassay (LFA) to detect for EpCAM. Combinations of anti-EpCAM antibodies were first screened using the product, from which we were able to successfully see strong binding on spot tests in duplicate for certain antibody combination pairs. These tests allowed us to confidently move forward with printing and assembling proper LFAs.
- J***a2021-09-17 0Mettre un likeWe received the product with a fairly fast speed, we used this product for antibody screening and ELISA. The product is robust and good quality.
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Avis sur les produits
- Informations sur les médicaments cliniques
Partager vers :